(buta-2,3-dien-1-yl)({4-[(buta-2,3-dien-1-yl)amino]butyl})amine dihydrochloride

• ChemBase ID: 154886
• Molecular Formular: C12H22Cl2N2
• Molecular Mass: 265.22248
• Monoisotopic Mass: 264.11600407
• SMILES: C=C=CCNCCCCNCC=C=C.Cl.Cl
• Canonical SMILES: C=C=CCNCCCCNCC=C=C.Cl.Cl
• InChI: InChI=1S/C12H20N2.2ClH/c1-3-5-9-13-11-7-8-12-14-10-6-4-2;;/h5-6,13-14H,1-2,7-12H2;2*1H
• InChIKey: ITVRWVVFVHINOH-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: (buta-2,3-dien-1-yl)({4-[(buta-2,3-dien-1-yl)amino]butyl})amine dihydrochloride
• IUPAC Traditional name: buta-2,3-dien-1-yl[4-(buta-2,3-dien-1-ylamino)butyl]amine dihydrochloride
• Synonyms: CPC-200; MDL-72527DA; N,N′-Bis(2,3-butadienyl)-1,4-butanediamine dihydrochloride; N1,N4-Bis(2,3-butadienyl)-1,4-butanediamine hydrochloride; MDL 72527

Database IDs

• CAS Number: 93565-01-6
• MDL Number: MFCD13152261
• PubChem SID: 162249024
• PubChem CID: 3035046

CALCULATED PROPERTIES

• H Acceptors: 2
• H Donor: 2
• LogD (pH = 5.5): -4.386984
• LogD (pH = 7.4): -2.1903088
• Log P: 1.9563842
• Molar Refractivity: 63.8166 cm^3
• Polarizability: 24.36867 Å^3
• Polar Surface Area: 24.06 Å^2
• Rotatable Bonds: 9
• Lipinski's Rule of Five: true

PROPERTIES

Physical Property

• Solubility: DMSO: ≥20 mg/mL
• Apperance: light yellow to light brown powder

Safety Information

• European Hazard Symbols: Irritant (Xi)
• German water hazard class: 3
• Risk Statements: 36/37/38
• Safety Statements: 26
• GHS Pictograms: GHS07
• GHS Signal Word: Warning
• GHS Hazard statements: H315-H319-H335
• GHS Precautionary statements: P261-P305 + P351 + P338
• Storage Temperature: room temp

Product Information

• Purity: ≥98% (HPLC)
• Empirical Formula (Hill Notation): C12 H20 N2·2 HCl

DETAILS

Sigma Aldrich - M2949

Biochem/physiol Actions
MDL 72527is an inhibitor of polyamine oxidase (spermine oxidase SMO). It blocks the production of H2O2 and increases the cells survival. Polyamine catabolism is one of the major causes of the ROS production of prostate cells in general and androgen-induced enhancement of ROS in androgen-dependent CaP cells in particular. Reports suggest that androgen stimulation of prostate cancer results in accumulation of ROS, which lead to progression of cancer, such progression is control by MDL 72527.